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OBJECTIVES The purpose of this study was to assess the effectiveness of azimilide, a class III antiarrhythmic
drug, in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial
fibrillation, atrial flutter or both.
BACKGROUND Atrial fibrillation is an increasingly common disorder of the heart rhythm, and most patients
with this problem are identified because they have symptoms associated with their arrhyth-
mia. New antiarrhythmic therapies are needed to treat patients with this problem.
METHODS A total of 384 patients with a history of atrial fibrillation, atrial flutter or both were randomly
assigned to receive once daily doses of placebo or azimilide; recurrent symptomatic
arrhythmias were documented using transtelephonic electrocardiogram (ECG) recording.
Azimilide 50 mg, 100 mg or 125 mg was tested; the primary efficacy analysis compared the
time to first symptomatic recurrence in the combined azimilide 100 mg and 125 mg dose
groups with that in the placebo group using the log-rank test.
RESULTS In the primary efficacy analysis, the time to first symptomatic arrhythmia recurrence was
significantly prolonged in the combined azimilide 100 mg and 125 mg daily dose group
compared with the placebo group (chi-square 7.96, p 5 0.005); the hazard ratio (placebo:
azimilide) for this comparison was 1.58 (95% confidence interval [CI] 5 1.15, 2.16). In
comparisons between individual doses and placebo, the hazard ratio for the 50 mg daily dose
was 1.17 (95% CI 5 0.83, 1.66; p 5 0.37); for the 100 mg group, dose was 1.38 (95% CI 5
0.96, 1.98; p 5 0.08), and for the 125 mg group, dose was 1.83 (95% CI 5 1.24, 2.70; p 5
0.002).
CONCLUSIONS Azimilide significantly lengthened the symptomatic arrhythmia-free interval in patients with
a history of atrial fibrillation, atrial flutter or both. (J Am Coll Cardiol 2000;36:794–802) ©
2000 by the American College of Cardiology
Atrial fibrillation (AF) is a disorder of the heart rhythm in
which normal sinus rhythm is punctuated by periods of
abnormal rhythm that is recognized by patients as the
sudden onset of symptoms including palpitations, chest pain
and dyspnea. The Cardiovascular Health Study, a cohort
study that is following a population .65 years old, showed
that the incidence of atrial fibrillation is increasing and that
most patients are identified because they have symptoms
when their rhythm is abnormal (1). Current antiarrhythmic
drugs are limited in their use by imperfect efficacy and
uncertain safety. In addition, as the population ages, there
will be an increased need for new, convenient antiarrhyth-
mic drugs that reduce the frequency of symptomatic occur-
rences of atrial fibrillation. Azimilide is a novel class III
antiarrhythmic drug that blocks both IKr and IKs channels
and that has been developed for atrial fibrillation; the
combined effect of IKr and IKs blockade may decrease the
proarrhythmic potential of azimilide. Because clinical expe-
rience with azimilide is limited (2), in this study azimilide
doses of 50, 100 and 125 mg daily (QD) were evaluated to
test the hypothesis that azimilide lengthened the symptom-
atic arrhythmia-free period for patients with AF, atrial
flutter or both.
METHODS
Entry criteria. To be eligible, male or female patients with
age $18 years were required to have a history of symptom-
atic AF, atrial flutter or both and to be candidates for
antiarrhythmic therapy based on the judgment of the
investigator enrolling them. Investigators were required to
provide an electrocardiogram (ECG) showing AF or atrial
flutter that had been recorded within 24 months of the date
of randomization, and patients were required to be in sinus
rhythm at the time of randomization. Important cardiovas-
cular exclusions were angina at rest; symptoms of heart
failure at rest; thoracic surgery, cardiac surgery or myocar-
dial infarction within two months; a history of torsade de
pointes or any other polymorphic ventricular tachycardia;
resting heart rate ,50 beats/min or QTc on an ECG
recording in sinus rhythm .440. Other exclusion criteria
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were blood urea nitrogen .50 mg/dl or serum creatinine
.2.0 mg/dl.
Randomization and follow-up. A permuted block ran-
domization scheme was used to assign equal numbers of
patients to four treatment groups: placebo or azimilide
50 mg, 100 mg or 125 mg. The assigned treatment was
given twice a day (BID) for three days (the loading period)
and then the frequency was reduced to QD during the
efficacy period for up to 180 days. If a patient had a
symptomatic arrhythmia recurrence during the loading pe-
riod and the arrhythmia was present at midnight of day 3,
then the efficacy period was adjusted to begin at the first
time the patient had documented resumption of sinus
rhythm. If sinus rhythm was not restored (spontaneously or
by pharmacologic or direct current cardioversion) by day 10,
the patient was withdrawn from the trial.
When initiating randomized therapy, no titration was
used and no dose adjustments were made for weight,
gender, serum creatinine, associated diseases or concomitant
medications. Treatment was initiated in both inpatients and
outpatients. Symptomatic arrhythmia recurrence was docu-
mented using transtelephonic ECG monitoring. Electro-
cardiograms recorded during hospital stays or emergency
department visits also were obtained; all ECGs from symp-
tomatic arrhythmia recurrences were reviewed by an event
committee that was blinded to the patient’s treatment
assignment and arrhythmia history. Transtelephonic ECG
monitoring also was used every two weeks during follow-up
to record an ECG when patients were asymptomatic.
Patients completed follow-up by having a symptomatic
recurrence of their arrhythmia documented by ECG or by
finishing 180 days with no arrhythmia recurrence.
Data analysis. The protocol explicitly specified primary,
secondary and additional efficacy analyses. Statistical analy-
ses were done using SAS/STAT (SAS Institute Inc., Cary,
North Carolina). The primary outcome variable was the
time to first symptomatic arrhythmia recurrence docu-
mented by an ECG consistent with AF, atrial flutter or
paroxysmal supraventricular tachycardia (completion
events). The Kaplan-Meier life-table method was used to
display the outcome data and to estimate the median
recurrence time for each group (3). Differences between
groups were compared with the log-rank test. The Cox
proportional hazards model was used to calculate a hazard
ratio (placebo:azimilide) for each comparison (3).
The protocol-specified primary efficacy analysis compared
the placebo group with the combined 100 mg QD and
125 mg QD doses during the efficacy period (excluding the
three-day loading period); this analysis used a two-sided
log-rank test and alpha 5 0.05. Combining the 100 mg and
125 mg dose groups increased the statistical power of the
primary data analysis compared with doing multiple analy-
ses of individual doses. Additional protocol-specified effi-
cacy analyses compared individual doses with placebo.
Because the primary efficacy analysis excluded symptom-
atic arrhythmia events that occurred during the loading
period, all efficacy analyses were repeated using data from
the loading period as well as the efficacy period (called day
1 analyses). These latter analyses, which were specified in
the protocol, were planned to assess whether including the
loading period, when blood azimilide concentrations should
have been lower compared with the efficacy period, de-
creased the magnitude of the treatment effect.
A log-rank trend test was done across all doses to test for
a dose response. A secondary efficacy analysis specified in
the protocol compared heart rate during arrhythmia recur-
rences. Finally, asymptomatic arrhythmia occurrences were
tabulated in the four treatment groups in an exploratory
analysis.
Adverse events were counted for all randomized patients
from day 1 and, therefore, included both the loading period
and the efficacy period. Patients were required to withdraw
for QTc .525. Adverse events were included in the safety
analysis if they occurred within 30 days of patient with-
drawal for any reason. Safety variables reported here are
deaths, torsades de pointes, withdrawal for 12-lead ECG
with QTc $525 and withdrawals for any other adverse
event. The QTc was measured on day 4 from a 12-lead
ECG and compared with the QTc measured on a baseline
(pretreatment) ECG.
Study chronology. The first patient was enrolled on Sep-
tember 4, 1996, and the last patient finished follow-up on
October 6, 1997. The protocol was approved by an institu-
tional review board for clinical investigations at each study
site. One protocol amendment was filed to change the
statistical analysis plan; this amendment was filed before the
study data base was locked or unblinded.
RESULTS
Study population. A total of 384 patients were recruited at
97 sites and randomized among the four treatments: 93
patients to placebo, 101 patients to azimilide 50 mg QD, 97
to 100 mg QD and 93 to 125 mg QD. Twenty-eight
patients (5.3%) were in the hospital at the time they received
their first dose of blinded therapy. Demographic and base-
line cardiovascular characteristics were well balanced among
the treatment groups (Table 1) as was the use of common
concomitant medications (Table 2). Overall 76.8% of pa-
tients had some form of structural heart disease, which was
defined as a diagnosis of coronary artery disease (with or
without myocardial infarction), congestive heart failure,
valvular heart disease, hypertension with cardiomyopathy,
Abbreviations and Acronyms
AF 5 atrial fibrillation
BID 5 twice daily
CI 5 confidence interval
ECG 5 electrocardiogram
QD 5 daily
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hypertension with left ventricular hypertrophy, left atrial
enlargement by echocardiogram or conduction system dis-
ease. Thirty-four percent had a history of treatment with
direct current cardioversion before randomization.
About one-third of the patients had a history of multiple
arrhythmias recorded by ECG before randomization. Only
61% of patients had just a history of AF while 7% had just
atrial flutter. Seventeen percent had prior ECGs showing
both AF and atrial flutter and 13% had prior ECGs
showing AF or atrial flutter and another regular rhythm
without evident atrioventricular dissociation that was typical
for paroxysmal supraventricular tachycardia.
Primary efficacy analysis. Among the 384 randomized
patients, 367 entered the efficacy period in sinus rhythm
after the end of the loading period. The primary efficacy
analysis compared placebo patients (n 5 87) who entered
the efficacy period with a combined group of patients who
received azimilide 100 mg QD and patients who received
azimilide 125 mg QD (n 5 181). The log-rank test p value
for this comparison was 0.005 (chi-square 7.96), and the
hazard ratio was 1.58 (95% confidence interval [CI] 5 1.15,
2.16). The median time to completion event in the placebo
group was 17 days compared with 60 days in the combined
azimilide group (Fig. 1). The result of the primary efficacy
analysis was consistent across subgroups (Fig. 2); that is,
efficacy in none of the subgroups was significantly different
from efficacy in the overall primary analysis.
When the loading period (day 1 to day 3) and the efficacy
period were both included in the comparison of placebo
(n 5 93) with the combined azimilide group (n 5 190),
evidence of efficacy was comparable: chi-square 9.4, p 5
0.002; hazard ratio 1.61 (95% CI 5 1.19, 2.19). There
appeared to be a very small, but favorable, effect of azimilide
during the loading period; 19.3% of placebo patients had
Table 1. Demographic and Baseline Cardiac Characteristics
Parameter
Azimilide
50 mg
n 5 101
Azimilide
100 mg
n 5 97
Azimilide
125 mg
n 5 93
Placebo
n 5 93
Age (yrs)* 64.9 6 11.7 64.2 6 11.7 63.4 6 11.9 63.1 6 11.8
Sex†
Male 60 (59%) 58 (60%) 65 (70%) 57 (61%)
Female 41 (41%) 39 (40%) 28 (30%) 36 (39%)
Race†
Caucasian 100 (99%) 94 (97%) 89 (96%) 92 (99%)
Hispanic 0 2 (2%) 2 (2%) 0
Black 1 (1%) 0 2 (2%) 1 (1%)
Other 0 1 (1%) 0 0
Heart rate (beats/min)* 66.8 6 13.5 66.3 6 12.3 66.0 6 12.3 65.1 6 10.6
QT Interval (ms)* 378.9 6 30.3 380.9 6 35.8 380.5 6 30.9 377.3 6 29.5
QTc Interval (ms)* 396.2 6 32.2 396.6 6 28.8 395.7 6 30.0 390.2 6 24.9
Congestive heart failure† 23 (23%) 13 (13%) 16 (17%) 17 (18%)
Ischemic heart disease† 31 (31%) 32 (33%) 33 (35%) 24 (26%)
Hypertension† 57 (56%) 47 (48%) 57 (61%) 63 (68%)
Valvular disease† 57 (56%) 48 (49%) 49 (53%) 46 (49%)
Cardiomyopathy† 12 (12%) 10 (10%) 12 (13%) 8 (9%)
Conduction system 11 (11%) 8 (8%) 6 (6%0 11 (12%)
Disease†
Structural heart disease 74 (73%) 73 (75%) 71 (76%) 77 (83%)
*Data shown are mean 6 standard deviation; †Data shown are number and percent of patients in the category.
Table 2. Selected Concomitant Medications
Therapeutic Category
50 mg
n 5 101
100 mg
n 5 97
125 mg
n 5 93
Placebo
n 5 93
Cardiac glycosides 58 (57%) 55 (57%) 50 (54%) 57 (61%)
Calcium channel blockers
Diltiazem 17 (17%) 14 (14%) 16 (17%) 10 (11%)
Dihydropyridines 9 (9%) 8 (8%) 13 (14%) 6 (7%)
Verapamil 15 (15%) 14 (14%) 13 (14%) 15 (16%)
Warfarin 53 (53%) 37 (38%) 38 (41%) 40 (43%)
Aspirin 26 (26%) 21 (22%) 27 (29%) 23 (25%)
Beta-blockers 32 (32%) 26 (27%) 27 (29%) 27 (29%)
Angiotensin-converting enzyme inhibitors 26 (26%) 21 (22%) 27 (29%) 23 (25%)
Diuretics 27 (27%) 19 (20%) 23 (25%) 27 (29%)
Potassium supplements 22 (22%) 10 (10%) 15 (16%) 15 (16%)
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events during the loading period compared with 15.8% of
azimilide (100 and 125 mg) patients.
Individual dose efficacy. Higher doses of azimilide were
associated with better efficacy (Fig. 3) in the comparison of
individual dose groups with the placebo group measured
during the efficacy period. A log-rank trend test across all
doses was significant (chi-square 5 9.8, p 5 0.002); that is,
as dose increased from placebo to 125 mg QD, efficacy
improved. The hazard ratios uniformly improved across
doses: 50 mg 1.17 (95% CI 5 0.83, 1.66; p 5 0.37), 100 mg
1.38 (95% CI 5 0.96, 1.98; p 5 0.08) and 125 mg 1.83
(95% CI 5 1.24, 2.70; p 5 0.002). Also, the median time
to first symptomatic arrhythmia recurrence was 17 days in
the placebo group compared to 22 days in the azimilide
50 mg QD group, 41 days in the 100 mg group and
130 days in the 125 mg group.
Effect of azimilide on arrhythmia and heart rate recorded
during completion event and on asymptomatic arrhyth-
mias. The Event Committee interpreted ECGs recorded
at the time of completion events as AF in 92% of placebo
patients, 86% of the azimilide 50 mg QD group, 95% of the
100 mg QD group and 98% of 125 mg QD group. The few
remaining ECGs were consistent with atrial flutter or were
typical of paroxysmal supraventricular tachycardia.
Figure 1. Primary efficacy analysis. Time to symptomatic arrhythmia recurrence was significantly longer in the combined azimilide 100 mg QD and 125 mg
QD dose group compared with the placebo group (chi-square 7.96, p 5 0.005). QD 5 daily.
Figure 2. Efficacy in subgroups. None of the subgroups demonstrated efficacy that was significantly different from the overall primary efficacy analysis.
CHF 5 congestive heart failure; HD 5 heart disease; SHD 5 structural heart disease.
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The mean heart rates shown on the ECGs recorded at
the time of completion events were 123.1 beats per min in
the placebo group compared with 113.1 beats per min in the
azimilide 50 mg QD group (p 5 0.04), 112.9 in the 100 mg
QD group (p 5 0.06) and 113.6 in the 125 mg QD group
(p 5 0.08). For the comparison of groups used in the
primary efficacy analysis (combined azimilide 100 mg and
125 mg dose group with placebo, as specified in the
protocol), the heart rate on azimilide was significantly
slower (123.1 beats/min vs. 113.2 beats/min, p 5 0.04).
Asymptomatic atrial fibrillation and atrial flutter were
occasionally recorded by transtelephonic ECG monitoring
at the time of the biweekly routine contacts. These asymp-
tomatic rhythms were recorded from 9.2% of patients in the
placebo group compared with 8.1% of the azimilide 50 mg
QD group, 4.3% of the 100 mg dose group and 4.4% of the
125 mg dose group (p . 0.20 for all comparisons vs.
placebo).
Safety. The variables analyzed to assess safety in all ran-
domized patients included deaths, episodes of torsade de
pointes and withdrawals due to adverse events. There were
no deaths in the placebo group or the azimilide 100 mg dose
group; there were two deaths in the azimilide 50 mg dose
group and one in the 125 mg group. One of the deaths in
patients receiving azimilide 50 mg QD was a 71-year-old
woman who died of a stroke 29 days after beginning
randomized therapy and 21 days after discontinuing ran-
domized therapy. The other death in a patient receiving
azimilide 50 mg QD was unobserved, presumed sudden
death 35 days after randomization. This patient was a
61-year-old man with diabetes and a history of myocardial
infarction and exercise-induced angina. The death in a
patient receiving azimilide 125 mg QD was a 70-year-old
man with a history of coronary artery disease, bypass
grafting, heart failure, stroke, transient ischemic attacks and
carotid endarterectomy two weeks before randomization.
This patient had unwitnessed and presumed sudden death
eight days after randomization.
One patient in the 100 mg dose group, an 86-year-old
woman, had torsade de pointes on day 4 of blinded therapy
while she was in atrial flutter with 2.72 s pauses. She
recovered and discontinued protocol therapy.
The QTc measured on day 4 was compared with the
baseline QTc and showed a mean (6 standard deviation)
change of 11.0% (66.6%), 15.3% (68.2%), 16.2%
(68.3%), 18.5% (69.1%) in the placebo, 50 mg, 100 mg
and 125 mg azimilide groups, respectively. Seven patients
were required to withdraw for QTc .525 on ECGs
recorded 4 to 187 days after randomization. One of these
patients was receiving azimilide 50 mg QD, three were
receiving 100 mg QD, and three were receiving 125 mg
QD. In addition, withdrawal from the study due to an
adverse event occurred in 0, 4, 2 and 2 patients in the
placebo, 50 mg, 100 mg and 125 mg dose groups, respec-
tively. The four patients who withdrew from the azimilide
50 mg group had (one each) a skin rash, abnormal liver
function tests, diarrhea and a flu-like illness with weakness,
dizziness and paresthesias. Two patients withdrew from the
100 mg dose group for (one each) dizziness and syncope.
The latter patient was also taking the antiarrhythmic drug
disopyramide, a protocol violation; an explanation for the
syncope was not found. The two patients who withdrew
from the 125 mg dose group had nonsustained ventricular
tachycardia during hypokalemia (one patient) and prema-
ture ventricular beats (one patient).
DISCUSSION
Efficacy of azimilide. This randomized clinical trial dem-
onstrated that azimilide is an effective antiarrhythmic drug
Figure 3. Efficacy in individual doses compared with placebo. Time to first symptomatic arrhythmia recurrence increased across doses as the dose changed
from placebo to 50 mg QD, 100 mg QD and 125 mg QD. CHF 5 congestive heart failure; QD 5 daily.
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to reduce the frequency of symptomatic arrhythmia recur-
rences in patients with AF, atrial flutter or both, and it
demonstrated the effective dose range for azimilide. In the
primary efficacy analysis, the combined azimilide 100 mg
and 125 mg dose group was significantly better than placebo
(p 5 0.005). The hazard ratio for this comparison was 1.58
(95% CI 5 1.15, 2.16), and the median time to first
symptomatic arrhythmia recurrence was lengthened from 17
days in the placebo group to 60 days in the combined
azimilide group. The analysis of individual doses defined
the effective dose range for azimilide. The 50 mg QD
dose showed no relevant treatment effect while the 100 mg
and 125 mg QD doses both showed clinically important
effects.
An event committee reviewed all ECGs from symptom-
atic events and classified completion events as most consis-
tent with either AF, atrial flutter or paroxysmal supraven-
tricular tachycardia, and AF was the rhythm recorded
during completion events in the vast majority of patients in
all treatment groups. Importantly, higher doses of azimilide
did not appear to increase the occurrence of atrial flutter
compared with AF as has been reported with some other
antiarrhythmic drugs (4). There was a modest decrease in
heart rate during completion events when the combined
azimilide 100 mg and 125 mg group was compared with the
placebo group. This decrease in heart rate, however, was not
accompanied by evidence of an increase in the occurrence of
asymptomatic arrhythmias detected by routine biweekly
monitoring (5). In fact, asymptomatic arrhythmias appeared
to decrease slightly or higher doses of azimilide although the
decrease was not statistically significant. It is not known, of
course, whether asymptomatic AF is associated with any
important adverse patient outcome, nor is it known whether
treating asymptomatic AF with an antiarrhythmic drug is
associated with beneficial effects. The effect of antiarrhyth-
mic therapy on asymptomatic arrhythmias, however, war-
rants further study.
Safety. More than 90% of patients began randomized
therapy with azimilide as an outpatient, and azimilide was
well tolerated. Torsade de pointes occurred in only one
patient in this study. Three deaths occurred during the
study. All occurred in patients with coronary artery disease,
and all were thought to have a cardiovascular cause. Two of
the deaths were in patients receiving azimilide 50 mg QD,
the lowest dose tested and a dose not associated with clinical
efficacy. An efficacy study of this size with only three deaths
among 384 randomized patients is insufficient to establish
the presence or absence of an effect of azimilide on mortal-
ity.
Patient withdrawals due to adverse events occurred infre-
quently and did not appear to increase with the higher doses
tested. A precise estimate, however, of the rate at which
these events occur in patients taking azimilide will require
studying more patients.
Trial design. This randomized trial included some novel
features. Simple inclusion and exclusion criteria were de-
signed to enroll a study population that was representative
of many patients with AF and atrial flutter who are
prescribed antiarrhythmic drug therapy; patients with all
types of AF were included rather than limiting the trial to a
single classification such as “paroxysmal” or “chronic” as has
been done in many previous trials (6–10). The patients’
arrhythmia histories demonstrated the frequent prior occur-
rence of multiple arrhythmias in these patients. Azimilide
predominantly was begun in an outpatient setting, and no
dose titration was used for patients receiving higher doses.
Transtelephonic ECG monitoring provided objective doc-
umentation of the rhythm at the time of symptoms, and
event committee review of all symptomatic ECGs assured a
uniform standard for interpretation of these ECGs.
Conclusions. Azimilide may be a promising new antiar-
rhythmic drug, but additional data on both efficacy and
safety are required to establish its role in clinical practice. In
this randomized clinical trial, azimilide was initiated in an
outpatient setting, was administered once daily, did not
require dose titration, showed promising efficacy and was
well tolerated.
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